clinical trial · NCT07100873
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Rheumatoid Arthritis (RA)ADI-001FludarabineCyclophosphamide
brief summary
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
started
Oct 10, 2025
primary completion
Mar 30, 2027
completion
Mar 30, 2028
last updated
Dec 8, 2025
official title
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Treatment-refractory Rheumatoid Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol